Clinical and pharmacokinetic study of oral etoposide in patients with AIDS-related Kaposi's sarcoma with no prior exposure to cytotoxic therapy

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
G SchwartsmannD R Mans

Abstract

In this phase II and pharmacokinetic study, chronic, low-dose, oral etoposide was evaluated for its efficacy in patients with AIDS-related Kaposi's sarcoma who were not previously exposed to cytotoxic therapy. Of 28 patients accrued for the study, 25 were assessable for toxicity and response. Twenty-four patients were male (homosexual or bisexual cases) and one patient was female (partner of a bisexual male). All patients were human immunodeficiency virus (HIV)-positive, New York University (NYU) disease stage IIB to IVB, and most exhibiting skin and lymph node and/or visceral disease. Median age was 33 years (range, 21 to 50), and median World Health Organization (WHO) performance status was 2 (range, 0 to 3). The patients received a mean number of six treatment courses (range, four to 27). Prior therapy included local/regional irradiation, immunotherapy (interferon-alpha), local resection, and/or cryotherapy. No prior cytotoxic therapy was allowed. Etoposide was administered at a schedule of 25 mg/m2 orally, twice a day for 7 days, every 2 weeks. Plasma concentrations of the drug were measured in six patients by a high-performance liquid chromatography (HPLC) method, after chloroform extraction using teniposide as internal st...Continue Reading

Citations

Dec 13, 2000·Biopharmaceutics & Drug Disposition·J KuntaP J Sinko
Mar 23, 2017·Journal of Obstetrics and Gynaecology : the Journal of the Institute of Obstetrics and Gynaecology·Yakup BozkayaNurullah Zengin
May 25, 2004·Expert Opinion on Investigational Drugs·Anna Maria CattelanSavina Maria Lucia Aversa
Sep 29, 2005·Journal of Pediatric Hematology/oncology·Alessandro SandriEnrico Madon
Feb 23, 2019·Journal of the National Comprehensive Cancer Network : JNCCN·Erin ReidDeborah A Freedman-Cass
May 14, 2004·Clinical Pharmacokinetics·Giuseppe ToffoliMauro Boiocchi
Aug 16, 2002·American Journal of Clinical Dermatology·Anna M CattelanSavina M L Aversa
Aug 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Scott R EvansJamie H Von Roenn
Feb 19, 2005·Critical Reviews in Oncology/hematology·Savina Maria Lucia AversaSilvio Monfardini

❮ Previous
Next ❯

Related Concepts

Related Feeds

HIV/AIDS-Related Malignancies

HIV/AIDS infection increases the risk of non-communicable diseases common in the aged including HIV/AIDS-related malignancies. Discover the latest research in HIV/AIDS-related malignancies.

AIDS Malignancies (ASM)

HIV infection increases the risk of non-communicable diseases common in the aged, including cardiovascular disease, neurocognitive decline, non-aids malignancies, osteoporosis, and frailty. Discover the latest research in AIDS malignancies.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Guglielmo NastiUmberto Tirelli
International Journal of Radiation Oncology, Biology, Physics
M E SteinW R Bezwoda
Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
U MetzmannJ Kutzner
© 2021 Meta ULC. All rights reserved